CA2332336A1 - Procede permettant d'augmenter des lymphocytes b de primates chez la souris immunodeprimee, et de produire de grands nombres de lymphocytes b specifiques de l'antigene pour la production d'anticorps monoclonaux de primates - Google Patents
Procede permettant d'augmenter des lymphocytes b de primates chez la souris immunodeprimee, et de produire de grands nombres de lymphocytes b specifiques de l'antigene pour la production d'anticorps monoclonaux de primates Download PDFInfo
- Publication number
- CA2332336A1 CA2332336A1 CA002332336A CA2332336A CA2332336A1 CA 2332336 A1 CA2332336 A1 CA 2332336A1 CA 002332336 A CA002332336 A CA 002332336A CA 2332336 A CA2332336 A CA 2332336A CA 2332336 A1 CA2332336 A1 CA 2332336A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- human
- primate
- mice
- scid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 215
- 210000004027 cell Anatomy 0.000 title claims abstract description 195
- 241000699670 Mus sp. Species 0.000 title claims abstract description 111
- 241000288906 Primates Species 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title claims abstract description 90
- 239000000427 antigen Substances 0.000 title claims abstract description 77
- 108091007433 antigens Proteins 0.000 title claims abstract description 77
- 102000036639 antigens Human genes 0.000 title claims abstract description 77
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title description 36
- 210000000952 spleen Anatomy 0.000 claims abstract description 105
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 87
- 239000007924 injection Substances 0.000 claims abstract description 30
- 238000002347 injection Methods 0.000 claims abstract description 30
- 238000004113 cell culture Methods 0.000 claims abstract description 13
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 11
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 11
- 238000010171 animal model Methods 0.000 claims abstract description 10
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 claims abstract description 8
- 241000282414 Homo sapiens Species 0.000 claims description 263
- 210000000265 leukocyte Anatomy 0.000 claims description 147
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 76
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 63
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 63
- 210000005260 human cell Anatomy 0.000 claims description 57
- 210000000822 natural killer cell Anatomy 0.000 claims description 46
- 241001465754 Metazoa Species 0.000 claims description 21
- 210000005259 peripheral blood Anatomy 0.000 claims description 15
- 239000011886 peripheral blood Substances 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 13
- 239000012678 infectious agent Substances 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 5
- 230000002607 hemopoietic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000011579 SCID mouse model Methods 0.000 description 87
- 238000010186 staining Methods 0.000 description 56
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 48
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 37
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 37
- 230000028993 immune response Effects 0.000 description 36
- 238000002054 transplantation Methods 0.000 description 28
- 210000004698 lymphocyte Anatomy 0.000 description 26
- 210000004989 spleen cell Anatomy 0.000 description 26
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 25
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 25
- 241001529936 Murinae Species 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 238000001727 in vivo Methods 0.000 description 25
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 24
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 238000002203 pretreatment Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 238000007912 intraperitoneal administration Methods 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 210000004303 peritoneum Anatomy 0.000 description 21
- 230000004913 activation Effects 0.000 description 20
- 210000004379 membrane Anatomy 0.000 description 20
- 239000012528 membrane Substances 0.000 description 20
- 238000012546 transfer Methods 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 18
- 108010055044 Tetanus Toxin Proteins 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 229940118376 tetanus toxin Drugs 0.000 description 14
- 238000002649 immunization Methods 0.000 description 13
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 12
- 238000011789 NOD SCID mouse Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000000763 evoking effect Effects 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 241000711549 Hepacivirus C Species 0.000 description 10
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 101150013553 CD40 gene Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 210000004180 plasmocyte Anatomy 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000007928 intraperitoneal injection Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 102100027207 CD27 antigen Human genes 0.000 description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 7
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 7
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000028996 humoral immune response Effects 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 7
- 230000003844 B-cell-activation Effects 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 210000005210 lymphoid organ Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 229960000074 biopharmaceutical Drugs 0.000 description 5
- 210000003969 blast cell Anatomy 0.000 description 5
- 230000001143 conditioned effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 201000005404 rubella Diseases 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 102100025221 CD70 antigen Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000012809 post-inoculation Methods 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 241001272567 Hominoidea Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 3
- 244000166550 Strophanthus gratus Species 0.000 description 3
- 201000005485 Toxoplasmosis Diseases 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000011748 cell maturation Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000000207 lymphocyte subset Anatomy 0.000 description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 description 3
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 3
- 229960003343 ouabain Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- SCLAUTQTMPTDII-LFIBNONCSA-N (5e)-2-(2-chloroanilino)-5-[[4-(dimethylamino)phenyl]methylidene]-1,3-thiazol-4-one Chemical compound C1=CC(N(C)C)=CC=C1\C=C\1C(=O)N=C(NC=2C(=CC=CC=2)Cl)S/1 SCLAUTQTMPTDII-LFIBNONCSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 101100485276 Arabidopsis thaliana XPO1 gene Proteins 0.000 description 1
- 102100038105 Arpin Human genes 0.000 description 1
- 201000008162 B cell deficiency Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 229940124884 Engerix-B Drugs 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 101001093025 Geobacillus stearothermophilus 50S ribosomal protein L7/L12 Proteins 0.000 description 1
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 241000288903 Lemuridae Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000562356 Polietes Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100407739 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PET18 gene Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 101100202463 Schizophyllum commune SC14 gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- -1 fluoresceine isothiocyanate Chemical class 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000053350 human FCGR3B Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 101150112970 up gene Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un procédé permettant de conférer des cellules de primate à une souris immunodéprimée. Ce procédé comprend les étapes consistant à: (a) préparer une souris immunodéprimée en lui administrant un anticorps contre la chaîne béta du récepteur (IL-2) de l'interleukine 2 de la souris, et plus particulièrement, l'anticorps monoclonal TM-.beta.1 de la souris et/ou en la soumettant à un rayonnement gamma; et (b) à administrer, par injection dans la rate de la souris immunodéprimée pré-traitée des cellules de primate. Ces cellules de primate proviennent, de préférence, d'un donneur primate et ce donneur peut avoir été immunisé par un antigène bien défini. Ce procédé permet d'augmenter de manière appropriée des lymphocytes B de primates chez un modèle animal avec rapidité et sans égal. D'autres modes de réalisation de la présente invention concernent des souris immunodéprimées obtenues par le procédé susmentionné et également l'utilisation de ces dernières comme modèles animaux, des cultures de lymphocytes B de primates ainsi produits et des anticorps monoclonaux de primates dérivés de ces dernières.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98870121.5 | 1998-05-26 | ||
EP98870121 | 1998-05-26 | ||
PCT/EP1999/003605 WO1999060846A1 (fr) | 1998-05-26 | 1999-05-25 | Procede permettant d'augmenter des lymphocytes b de primates chez la souris immunodeprimee, et de produire de grands nombres de lymphocytes b specifiques de l'antigene pour la production d'anticorps monoclonaux de primates |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2332336A1 true CA2332336A1 (fr) | 1999-12-02 |
Family
ID=8237050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002332336A Abandoned CA2332336A1 (fr) | 1998-05-26 | 1999-05-25 | Procede permettant d'augmenter des lymphocytes b de primates chez la souris immunodeprimee, et de produire de grands nombres de lymphocytes b specifiques de l'antigene pour la production d'anticorps monoclonaux de primates |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1079688A1 (fr) |
AU (1) | AU751647B2 (fr) |
CA (1) | CA2332336A1 (fr) |
WO (1) | WO1999060846A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
ATE321069T1 (de) | 2000-05-12 | 2006-04-15 | Vlaams Interuniv Inst Biotech | Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) |
CA2402459A1 (fr) | 2000-12-01 | 2002-06-06 | Central Institute For Experimental Animals | Procede pour produire une souris adaptee aux greffes, a la differenciation et a la proliferation de cellules heterogenes, souris obtenue selon cette methode et utilisation de la souris |
EP1474444A1 (fr) | 2002-01-10 | 2004-11-10 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Nouveau variant a epissage du myd88 et utilisations correspondantes |
BRPI0609151B8 (pt) | 2005-03-24 | 2021-05-25 | Life Sciences Res Partners Vzw | molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo |
US7867490B2 (en) | 2005-06-30 | 2011-01-11 | Vib Vzw | Treatment of liver cirrhosis and its complications |
DK2352761T3 (en) | 2008-10-02 | 2016-10-03 | Vib Vzw | INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOMPOSITIVE LEUKEMIS |
EP2756092A4 (fr) * | 2011-09-16 | 2015-10-28 | Giovanni Amabile | Procédés de fabrication de cellules, de tissus et d'anticorps |
AU2012321082B2 (en) | 2011-12-01 | 2015-03-12 | Oxurion NV | Improving trabeculectomy outcome |
EP2914628A1 (fr) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | Anticorps qui se lie à cd269 (bcma) pouvant être utilisé dans le traitement de maladies des cellules plasmatiques comme le myélome multiple et les maladies auto-immunes |
AR093447A1 (es) * | 2012-11-13 | 2015-06-10 | Genentech Inc | Enriquecimiento de plasmablastos especificos de antigeno |
WO2017132627A2 (fr) | 2016-01-29 | 2017-08-03 | Achaogen, Inc. | Procédés de criblage permettant d'identifier des anticorps qui se lient à des épitopes à la surface des cellules |
CA3026778A1 (fr) | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Recepteur d'antigene chimere et cellules t-car se liant a bcma |
CN111094349A (zh) | 2017-08-23 | 2020-05-01 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 嵌合抗原受体和结合cxcr5的car-t细胞 |
US20210230245A1 (en) | 2018-04-20 | 2021-07-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
ES2967879T3 (es) | 2019-03-25 | 2024-05-06 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9 |
JP2023540023A (ja) | 2020-08-24 | 2023-09-21 | シャリテ-ウニベルジテーツメディツィン ベルリン | Ceaを認識するキメラ抗原受容体(car)発現細胞 |
EP4199959A1 (fr) | 2020-08-24 | 2023-06-28 | Charité - Universitätsmedizin Berlin | Construction de récepteur antigénique chimérique codant pour une molécule inhibitrice de point de contrôle et une cytokine immunostimulante et cellules exprimant car reconnaissant cd44v6 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2071620T3 (es) * | 1987-12-23 | 1995-07-01 | Univ Leland Stanford Junior | Mamiferos inmunodeficientes quimericos y su utilizacion. |
WO1993005796A1 (fr) * | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Procede de production d'anticorps humains dans un animal non humain, et animaux utilises a cet effet |
CA2103693A1 (fr) * | 1993-08-06 | 1995-02-07 | Steven Gallinger | Modele animal du systeme immunitaire humain |
AU6222996A (en) * | 1995-06-07 | 1996-12-30 | Novartis Ag | Human hepatocellular tissue in chimeric immunocompromised an imals |
-
1999
- 1999-05-25 CA CA002332336A patent/CA2332336A1/fr not_active Abandoned
- 1999-05-25 EP EP99926411A patent/EP1079688A1/fr not_active Withdrawn
- 1999-05-25 AU AU43681/99A patent/AU751647B2/en not_active Ceased
- 1999-05-25 WO PCT/EP1999/003605 patent/WO1999060846A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU4368199A (en) | 1999-12-13 |
AU751647B2 (en) | 2002-08-22 |
WO1999060846A1 (fr) | 1999-12-02 |
EP1079688A1 (fr) | 2001-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU751647B2 (en) | Method for expanding primate B cells selectively in immunocompromised mice and producing large numbers of antigen-specific B lymphocytes for the production of primate monoclonal antibodies | |
Seebach et al. | Xenogeneic human anti‐pig cytotoxicity mediated by activated natural killer cells | |
Lee et al. | Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. | |
Lubin et al. | Engraftment of human peripheral blood lymphocytes in normal strains of mice | |
US5665557A (en) | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof | |
Wu et al. | Follicular dendritic cell-derived antigen and accessory activity in initiation of memory IgG responses in vitro. | |
US5849288A (en) | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells | |
DK1648507T3 (en) | PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS | |
US5677136A (en) | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof | |
US6056956A (en) | Non-depleting anti-CD4 monoclonal antibodies and tolerance induction | |
US5985660A (en) | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation | |
US20150299315A1 (en) | Non-b-lineage cells capable of producing antibody | |
US20070067854A1 (en) | Chimeric mouse having an immune system constructed with human CD34+ cells and use thereof | |
CA2402459A1 (fr) | Procede pour produire une souris adaptee aux greffes, a la differenciation et a la proliferation de cellules heterogenes, souris obtenue selon cette methode et utilisation de la souris | |
JPH0198477A (ja) | IgGモノクローナル抗体−生産性ハイブリドマ | |
CA2142989A1 (fr) | Nouvelle lignee cellulaire du lymphome a cellules b et antigene | |
US20190127464A1 (en) | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies | |
Vandekerckhove et al. | Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. | |
Depraetere et al. | Human B cell growth and differentiation in the spleen of immunodeficient mice | |
US20230330143A1 (en) | Immunotherapy composition | |
Malkovska et al. | Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity | |
JP2006122054A (ja) | 骨髄始原細胞および/またはリンパ系始原細胞について富化される細胞集団、ならびに製造方法および使用方法 | |
Mårtensson et al. | Antigen-specific human immunoglobulin production in SCID mice transplanted with human peripheral lymphocytes is dependent on CD4+ CD45RO+ T cells. | |
WO2001089539A2 (fr) | Methodes de retablissement ou de stimulation de l'immuno-surveillance des cellules t suite a l'immunosupression induite par voie naturelle ou artificielle | |
US5972627A (en) | Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |